NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LJB Laura J. Bornheimer GWN SECURITIES Inc. | 22,644 | $297,769 | $366,932.43 | $69,163.43 | 23.23% |
Anthony Scaramucci SkyBridge Capital II LLC | 692,000 | $8.22M | $11.18M | $2.96M | 36.02% |
Point72 Asset Management LP Point72 Asset Management LP | 152,025 | $2.06M | $2.46M | $403,477.98 | 19.63% |
Joseph Castro Nuveen LLC | 89,287 | $1.28M | $1.45M | $170,545.85 | 13.36% |
| SE Sima Elimelech Activest Wealth Management | 125 | $1,643.75 | $2,058.75 | $415 | 25.25% |
| Health Care Equipment & Supplies Industry | Healthcare Sector | Joel D. Becker CEO | NASDAQ (NMS) Exchange | 641288105 CUSIP |
| US Country | 220 Employees | - Last Dividend | - Last Split | 22 Apr 2021 IPO Date |
NeuroPace, Inc. is a medical device company based in the United States, specifically headquartered in Mountain View, California. Founded in 1997, the company focuses on developing innovative solutions for patients with medically refractory focal epilepsy. Its flagship product, the RNS System, represents a significant advancement in brain-responsive neuromodulation technology. This system offers personalized, real-time treatment by targeting the seizure source directly within the brain. Beyond its primary mission to improve the quality of life for individuals suffering from focal epilepsy, NeuroPace, Inc. takes pride in its contributions to the broader medical and scientific communities through continuous brain activity data collection. This data not only aids in the personal monitoring of patients by clinicians but also supports remote patient management, enhancing care delivery and patient outcomes.
The RNS System is NeuroPace, Inc.'s premier solution, comprising several components and services designed to support the needs of both patients and healthcare providers:
These products and services are delivered to hospital facilities across the United States, emphasizing the company's commitment to providing comprehensive solutions for the treatment and management of medically refractory focal epilepsy. Through its innovative offerings, NeuroPace, Inc. seeks to redefine the standard of care for epilepsy patients, offering them hope for a better quality of life.